Date: 2015-07-27
Type of information: Product acquisition
Compound: Caprelsa® (vandetanib)
Company: AstraZeneca (UK) Sanofi (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: product acquisition
Action mechanism: kinase inhibitor/tyrosine kinase inhibitor. This tyrosine kinase inhibitor is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).
Disease: symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease
Details: * On July 27, 2015, Sanofi and its subsidiary Genzyme announced that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a rare disease therapy, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease. Caprelsa® is currently available in 28 countries. Caprelsa® is in Phase III development for differentiated thyroid carcinoma, with the study expected to finish in the second half of 2015. The acquisition builds on Genzyme\'s long-standing commitment and scientific leadership in the field of endocrinology globally. The transaction is subject to closing conditions, including the receipt of antitrust clearance from the US Federal Trade Commission. The transaction is expected to complete in the second half of 2015.
Financial terms: Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300 million, including an upfront payment of $165 million to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities.
Latest news:
